What are the Implications of Mismatch Repair Deficiency in Cancer Treatment?
MMR deficiency has significant implications for cancer treatment. Tumors with defective MMR show high levels of mutations, making them more likely to respond to immunotherapy, particularly immune checkpoint inhibitors like pembrolizumab and nivolumab. These therapies enhance the body's immune response against cancer cells, leading to improved clinical outcomes in patients with MMR-deficient tumors.
